Switching from Tirzepatide to Semaglutide: Complete Guide: A Microdosing Perspective
Switching between GLP-1s on a microdose schedule is gentler than the weekly equivalent. Smaller daily doses give your body time to adapt at each step, and the lower peak concentrations reduce the side-effect spike that often hits during transitions. Microdose-to-microdose conversions can usually be done overnight; weekly-to-microdose transitions need a 1-2 week wash-down period. The conversion ratios below apply, with adjustments noted for split protocols.
Understanding the Medications
Research has established clear differences between these medications: Tirzepatide functions as a dual GIP/GLP-1 receptor agonist, while Semaglutide targets only GLP-1 receptors. This fundamental difference in mechanism of action explains why the transition between medications requires careful consideration.
Medication Comparison
Tirzepatide
- Dual GIP/GLP-1 agonist
- 2.5-15mg weekly
- Peak effect: 10-12 hours
- Half-life: ~5 days
- Generally milder GI effects
Semaglutide
- GLP-1 agonist only
- 0.25-2.4mg weekly
- Peak effect: 24-48 hours
- Half-life: ~7 days
- Moderate GI effects